AVBP ▲ +9.3% - ArriVent BioPharma, Inc.
$AVBP - ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
23-OCT-2026 04:00 PM ET
Share this post
More filings for $AVBP
AVBP ▲ +2.8% - ArriVent BioPharma, Inc.Oct 20, 2026AVBP ▲ +0.7% - ArriVent BioPharma, Inc.Oct 19, 2026AVBP ▼ -1.5% - ArriVent BioPharma, Inc.Oct 12, 2026AVBP - ArriVent BioPharma, Inc. - SEC Filing Update (08-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 8, 2026AVBP ▲ +0.8% - ArriVent BioPharma, Inc.Oct 6, 2026$AVBP SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026
View full $AVBP filing history →💬 Comments
Loading comments…
Leave a comment